production of PSG1-His protein, 10MG

FedBizOps Synopsis
Document Type: Combined Synopsis/Solicitation/Notice of Intent
Solicitation Number: NOI-RML-E-1760688
Posted Date:10/21/2015
Response Date: 10/28/2015
Set Aside: none
NAICS Code:325414
Classification Code: 66
Contracting Office Address:
Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 10401 Fernwood Drive MSC 4811 Room 2NE70-A, Bethesda, MD 20817

Title: production of PSG1-His protein, 10MG

Primary Point of Contact: Secondary Point of Contact
Jesse Weidow Barbara Horrell

Description:

This notice is a Notice of Intent. The Government intends to negotiate on a sole source basis with (R&D Systems) for the procurement of (production of PSG1-His protein, 10MG). This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 "Streamlined Procedures for Evaluation and solicitation for commercial Items," as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are not being requested and a written solicitation will not be issued. Submit offers on NOI-RML-E-1760688.

This acquisition is a Notice of Intent (NOI). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 05-83 August 4, 2015.
The North American Industry Classification System (NAICS) code for this procurement is 325414 with a small business size standard of (500). This requirement is not set aside for small business.

The National Institute of Allergy and Infectious Diseases (NIAID), is seeking to purchase the development of 10 MG of PSG1-His protein, Custom Development Recombinant Human PSG-1, mouse myeloma cell line, NS0¬-derived, aa1-419, with a C-¬terminal His tag, Accession # P11464. FOB Point shall be Destination; Bethesda, MD 20892.

Place of Performance:
NIH/NIAID
Bldg 10-CRC
10 Center Drive
Bethesda, MD 20892
United States

Award will be based on the capability of the item offered to meet the above stated salient characteristics, price, past performance, delivery, warranty, and the best value to the government.

The following FAR provisions apply to this acquisition:
52.212-1 Instructions to Offerors Commercial Items (April 2014)
FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (May 2014)
Offerors must complete annual representations and certifications on-line at http://www.sam.gov in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items
The following contract clauses apply to this acquisition:
FAR 52-212-4 Contract Terms and Conditions Commercial Items (May 2015)
FAR 52-212.5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (May 2015)
FAR 52.204-16 Commercial and Government Entity Code Reporting (July 2015)
FAR 52.204-18 Commercial and Government Entity Code Maintenance (July 2015)
52.203-98, Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements - Representation (DEVIATION 2015-02)
52.203-99, Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements - Representation (DEVIATION 2015-02)

The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting.

Quoter must include the following provision in their quote and check the appropriate response.
52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Dec 2014)
(a) Definitions. "Inverted domestic corporation" and "subsidiary" have the meaning given in the clause of this contract entitled Prohibition on Contracting with Inverted Domestic Corporations (52.209-10).
(b) Government agencies are not permitted to use appropriated (or otherwise made available) funds for contracts with either an inverted domestic corporation, or a subsidiary of an inverted domestic corporation, unless the exception at 9.108-2(b) applies or the requirement is waived in accordance with the procedures at 9.108-4.
(c) Representation. By submission of its offer, the offeror represents that- (check one)
____(1) It is not an inverted domestic corporation: and
____(2) It is not a subsidiary of an inverted domestic corporation

By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov).

Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov/far/loadmainre.html or, upon request, either by telephone or fax.

This is an open-market combined Notice of Intent for (production of PSG1-His protein, 10MG) as defined herein. The government intends to award a purchase order as a result of this combined synopsis/solicitation that will include the terms and conditions set forth herein. To facilitate the award process all quotes must include a statement regarding the terms and conditions herein as follows:
"The Terms and conditions in the solicitation are acceptable to be included in the award document without modification, deletion or addition."
OR
"The terms and conditions in the solicitation are acceptable to be included in the award document with the exception, deletion, or addition of the following:"
(Quoter shall list exception(s) and rationale for the exception(s).)

Submission shall be received not later than 10/28/2015 5:00 PM MST.

Offers may be mailed, e-mailed or faxed to Jesse Weidow; (Fax - 406-363-9288), (E-Mail/ weidowjd@niaid.nih.gov). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f)

All responsible sources may submit an offer that will be considered by this Agency.
Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to (weidowjd@niaid.nih.gov).
weidowjd@niaid.nih.gov